Exabis Library
Welcome to the e-CCO Library!
P528: Reducing intravenous monoclonal antibody observation times without compromising patient safety; a single-centre observational study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P529 Natural history and management strategies of ulcerative colitis (UC) in a paediatric population: A 10-year review in a tertiary paediatric gastroenterology centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P529: Adalimumab persistence and its biosimilar in inflammatory bowel disease: experience in a tertiary centre
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P529: Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID).
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P529: Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P529: Impact of stress in inflammatory bowel disease. Effect of a group psychological intervention program
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P529: Longer duration of vancomycin prevents recurrence of C. difficile in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P529: Year-two follow-up results of an observational study conducted in Crohn's disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life setting
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P530: Azathioprine in the maintenance of steroid-free remission in inflammatory bowel disease patients: efficacy and safety in five years of follow-up
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P530: Proactive therapeutic drug monitoring of anti-TNF agents is associated with higher mucosal healing rates in Crohn's disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P530: Psychosexual dysfunction in Greek patients with inflammatory bowel disease in remission
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P530: The Burden on Cohabitants of Patients with Inflammatory Bowel Disease: A Cross-Sectional Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P530: Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P530: Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P531 A retrospective audit of the inflammatory bowel disease specialist nurse-led telephone advice service
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P531: A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P531: Discontinuation of corticosteroids among Crohn's disease patients treated with vedolizumab in the United States
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P531: Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P531: SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM